This website uses cookies in order to improve our services. If you proceed visiting this website you accept the usage of cookies. For more info please read our Data Privacy statement.

 

Solid Tumors NGS Panels


General Cancer Testing | Brain & CNS Cancer | Breast & Ovarian Cancer | Colorectal & Prostate Cancer | Endocrine & Thyroid Cancer | Gastric Cancer | Hematologic Cancer | Kidney Cancer | Lung Cancer | Pancreatic Cancer | Skin Cancer & Melanoma | Solid Tumors | Less Common Cancers


The definition of solid tumors is an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer), or malignant (cancer). Different types of solid tumors are named for the type of cells that form them. Examples of solid tumors are sarcomas, carcinomas, and lymphomas (Source: NIH: Nation Cancer Institute).

On this page NGS panels that target genes that are frequently associated with solid tumor are listed. 

For more information on the targeted genes please contact the NGS panel provider, general information on different types of solid tumors are found on this website.


Solid Tumors

GeneTrailsTM solid tumor panel

Our GeneTrailsTM solid tumor panel (Ion Torrent® platform delivers information on 37 genes commonly involved in solid tumors. The panel has a sensitivity of ~5-15% mutant allele, depending upon the gene.
Source: Knight Diagnostic Laboratories

Human Tumor Actionable Mutations Panel

The Human Tumor Actionable Mutations GeneRead DNAseq Targeted Panel is a collection of multiplexed PCR primer assays for targeted enrichment of the key regions of 8 genes identified by the National Comprehensive Cancer Network (NCCN), College of American Pathologists (CAP), and American Society of Clinical Oncology (ASCO) to be clinically actionable somatic mutations in solid tumors.
Source:Qiagen

Solid Tumor Gene Set

Targeted genes: AKT1, AKT2, AKT3, ALK*, ATM, BAP1, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CREBBP, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FANCA, FGFR1, FGFR2*, FGFR3*, FGFR4, FLT1, FLT3, FLT4, GNAS, HRAS, IDH1, IDH2, JAK1, JAK2, KDR, KIT, KRAS, MAP2K1, MAP2K2, MET, MLH1, MTOR, MYC, NF1, NOTCH1, NOTCH2, NRAS, NTRK1*, PALB2, PDGFRA, PDGFRB, PIK3CA, PTEN, RAD54B, RB1, RET*, RIT1, ROS1*, SMAD4, STK11, TP53, TSC1, TSC2 and VHL (*rearrangements also detected
Source: WUSTL

SOLID TUMOR GENOTYPING PANEL

Screening for mutations in oncogenes and tumor suppressor genes is increasingly important in delivering personalized cancer care. The Solid Tumor Panel delivers information on 37 genes commonly involved in solid tumors. The panel has a sensitivity of ~5-15% mutant allele, depending on the gene.
Source: Responsegenetics

Website

Solid Tumor Mutation Panel

Useful for prognosis and/or treatment of individuals with
solid tumor cancers at initial diagnosis or in the presence of refractory disease
Genes – ABL1, AKT1, ALK, APC, ATM, BRAF, CDH1, CDKN2A,
CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, EZH2, FBXW7, FGFR1,
FGFR2, FGFR3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1,
IDH2, JAK3, KDR, KIT, KRAS, MET, MLH1, MPL, NOTCH1,
NPM1, NRAS, PDGFRA, PIK3CA, PTEN, PTPN11, RB1, RET,
SMAD4, SMARCB1, SMO, SRC, STK11, TP53, VHL
Source: Arup Laboratories

Solid Tumor Panel

Tested genes ABL1, AKT1, ALK, APC, AR, ARID1A, ASXL1, ATM, AXL, BRAF, CDH1, CDK4, CDKN2A, CTNNB1, DDR2, EGFR, ERBB2, FGFR1, FGFR2, FGFR3, FGFR4, GNA11, GNAQ, GNAS, HRAS, IDH1, IDH2, JAK2, JAK3, KDM6A, KDR, KIT, KRAS, MAP2K1, MET, MLH1, MLL, MLL2, MLL3, MTOR, NF1, NOTCH1, NRAS, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3R1, PTCH1, PTEN, PTPN11, RB1, RET, ROS1, SMAD4, SMARCA4, SMARCB1, SMO, STK11, TP53, TSC1, VHL

Source: Centogene

SOMATIC CANCER PANEL

he test detects mutations across 26 genes (targeted with 174 amplicons) in cancer cells, mutations which may be driving the growth of the cancer in patients with solid tumors. Many of these genes, including KRAS, EGFR and BRAF, have been associated with cancers such as melanoma, colorectal, ovarian and lung. With "somatic cancer panel", the DNA Research Center can detect mutations occurring even below 5% frequency reliably.

Source: DNA Research Center

SureSeq™ Solid Tumour Panel

The SureSeq™ Solid Tumour Panel is fully validated on FFPE samples, the 60-gene NGS SureSeq Solid Tumour Panel allows discovery of novel and known variants in a range of solid tumours.
Source: Oxford Gene Technology

Website

Targeted Tumor Mutation: Sequencing Panel

DNA isolated from solid tumors is hybridized using a library containing 175 exons in 26 different genes using next generation sequencing (NGS) at a minimum depth of 1000X. Each of these select exons contain pathogenic variants that are associated with cancer progression and resistance to therapy. Pathogenic variants are detected at a minimum 10% variant frequency enabling the detection of pathogenic variants in heterogeneous samples at a high read depth.
Targeted genes: (26)
Lung: AKT1, ALK, BRAF, CTNNB1, EGFR, KRAS, MAP2K1, MET, NRAS, PIK3CA, PTEN, TP53
Colon: AKT1, APC, BRAF, CTNNB1, EGFR, FBXW7, KRAS, MET, NRAS, PIK3CA, PTEN, SRC, TP53
Melanoma: BRAF, GNAQ, KIT, KRAS, MAP2K1, NRAS, PIK3CA, PTEN
Gastric: AKT1, BRAF, FGFR2, KIT, PDGFRA, PIK3CA, TP53
Ovarian: AKT1, BRAF, ERBB2, KRAS, PIK3CA, PTEN, TP53
Source: Emory Genetics Laboratory

TruSight Tumor

The TruSight Tumor sequencing panel takes a deeper view of variation in solid tumors including lung, colon, melanoma, gastric and ovarian. This enables clinical researchers to identify low-frequency variation across 26 genes for a more comprehensive view of somatic variation.
Source: Illumina

Website


Pin It